In this issue:
Use of the TNMB staging system for estimation of disease-free survival in NSCLC patients
Survival of NSCLC patients following addition of celecoxib to concurrent chemoradiation
Combination of ramucirumab and erlotinib for the treatment of EGFR-mutated metastatic NSCLC
Osimertinib for the treatment of NSCLC patients with uncommon EGFR mutations
Entrectinib treatment of ROS1 fusion-positive NSCLC
Crizotinib for the treatment of NSCLC patients with ROS1 or MET alterations
Early palliative care in patients with advanced lung cancer
Effect of early integrated palliative care on quality of life and healthcare utilisation in lung cancer patients
Preoperative radiotherapy plus perioperative chemotherapy in resectable gastric and GEJ cancers
MSI as a prognostic marker in resectable gastric cancer
Please login below to download this issue (PDF)